Ionis Pharmaceuticals Inc (NASDAQ:IONS) — Market Cap & Net Worth
Market Cap & Net Worth: Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Inc (NASDAQ:IONS) has a market capitalization of $7.85 Billion ($7.85 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2664 globally and #968 in its home market, demonstrating a -18.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ionis Pharmaceuticals Inc's stock price $47.25 by its total outstanding shares 166184322 (166.18 Million). Also see Ionis Pharmaceuticals Inc assets under control for a full breakdown of the balance sheet.
Ionis Pharmaceuticals Inc Market Cap History: 2015 to 2026
Ionis Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $10.29 Billion to $7.85 Billion (0.63% CAGR). Also see IONS cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Ionis Pharmaceuticals Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.68% | #16 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.30% | #65 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.02% | #308 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.42% | #45 of 263 |
Weight: Ionis Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ionis Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ionis Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Ionis Pharmaceuticals Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.93x
Ionis Pharmaceuticals Inc's market cap is 13.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.95 Billion | $346.62 Million | -$86.56 Million | 22.93x | N/A |
| 2017 | $8.36 Billion | $514.18 Million | $346.00K | 16.26x | 24159.17x |
| 2018 | $8.98 Billion | $599.67 Million | $273.74 Million | 14.98x | 32.82x |
| 2019 | $10.04 Billion | $1.12 Billion | $294.00 Million | 8.94x | 34.15x |
| 2020 | $9.40 Billion | $729.00 Million | -$487.00 Million | 12.89x | N/A |
| 2021 | $5.06 Billion | $810.46 Million | -$28.60 Million | 6.24x | N/A |
| 2022 | $6.28 Billion | $587.37 Million | -$269.72 Million | 10.69x | N/A |
| 2023 | $8.41 Billion | $787.65 Million | -$366.29 Million | 10.67x | N/A |
| 2024 | $5.81 Billion | $705.14 Million | -$453.90 Million | 8.24x | N/A |
| 2025 | $13.15 Billion | $944.00 Million | -$381.00 Million | 13.93x | N/A |
Competitor Companies of IONS by Market Capitalization
Companies near Ionis Pharmaceuticals Inc in the global market cap rankings as of September 16, 2026. Review tangible equity quality of Ionis Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ionis Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Ionis Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Ionis Pharmaceuticals Inc's market cap moved from $10.29 Billion to $ 7.85 Billion, with a yearly change of 0.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.85 Billion | -40.27% |
| 2025 | $13.15 Billion | +126.29% |
| 2024 | $5.81 Billion | -30.90% |
| 2023 | $8.41 Billion | +33.94% |
| 2022 | $6.28 Billion | +24.12% |
| 2021 | $5.06 Billion | -46.18% |
| 2020 | $9.40 Billion | -6.41% |
| 2019 | $10.04 Billion | +11.75% |
| 2018 | $8.98 Billion | +7.48% |
| 2017 | $8.36 Billion | +5.16% |
| 2016 | $7.95 Billion | -22.77% |
| 2015 | $10.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Ionis Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.85 Billion USD |
| MoneyControl | $7.85 Billion USD |
| MarketWatch | $7.85 Billion USD |
| marketcap.company | $7.85 Billion USD |
| Reuters | $7.85 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more